How many drugs treat Anesthesia for cesarean section?

Drug Landscape tracks 8 marketed treatments for Anesthesia for cesarean section (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/anesthesia-for-cesarean-section.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Anesthesia for cesarean section — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anesthesia for cesarean section (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Anesthesia for cesarean section, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Chirocain	LEVOBUPIVACAINE	Purdue Pharma Lp	levobupivacaine	Cytochrome P450 2D6	1999-01-01
Naropin	ROPIVACAINE	Fresenius Kabi	Amide Local Anesthetic	Sodium channel protein type 5 subunit alpha	1996-01-01
Bupivacaine Hydrochloride	Bupivacaine Hydrochloride	Pfizer	Amide-type local anesthetic	Nerve sodium channels	1972-01-01
Bupivacaine Hydrochloride And Epinephrine	BUPIVACAINE	Innocoll	Amide Local Anesthetic	Cytochrome P450 2D6	1972-01-01
Ropivacain	Ropivacain	University Hospital, Basel, Switzerland		Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha
Bupivacain	Bupivacain	Sisli Hamidiye Etfal Training and Research Hospital		5-hydroxytryptamine receptor 3A, Cytochrome P450 2D6, Potassium channel subfamily K member 3
Naropeine	Naropeine	University Hospital, Rouen		Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha
Naropine	Naropine	Rigshospitalet, Denmark		Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Fresenius Kabi · 1 drug in Anesthesia for cesarean section
Innocoll · 1 drug in Anesthesia for cesarean section
Pfizer · 1 drug in Anesthesia for cesarean section
Purdue Pharma Lp · 1 drug in Anesthesia for cesarean section
Rigshospitalet, Denmark · 1 drug in Anesthesia for cesarean section
Sisli Hamidiye Etfal Training and Research Hospital · 1 drug in Anesthesia for cesarean section
University Hospital, Basel, Switzerland · 1 drug in Anesthesia for cesarean section
University Hospital, Rouen · 1 drug in Anesthesia for cesarean section

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Anesthesia for cesarean section:

Cite this brief

Drug Landscape (2026). Anesthesia for cesarean section — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/anesthesia-for-cesarean-section. Accessed 2026-06-10.

Anesthesia for cesarean section full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing